公开(公告)号：EP1758874A1

公开(公告)日：2007-03-07

申请号：EP05748037.8

申请日：2005-05-30

申请人： 7TM Pharma A/S

发明人： ULVEN, Trond, 7TM Pharma A/S ,  FRIMURER, Thomas, 7TM Pharma A/S ,  RIST, Øystein, 7TM Pharma A/S ,  KOSTENIS, Evi, 7TM Pharma A/S ,  HÖGBERG, Thomas, 7TM Pharma A/S ,  RECEVEUR, Jean-Marie, 7TM Pharma A/S ,  GRIMSTRUP, Marie, 7TM Pharma A/S

IPC分类号： C07D277/30 ,  C07D417/06 ,  C07D417/04 ,  A61K31/426 ,  A61K31/427 ,  A61P11/06

CPC分类号： C07D277/30 ,  C07D417/04 ,  C07D417/06

摘要： Compounds of formula (I) are useful for the treatment of disease responsive to modulation of CRTH2 receptor activity, such as asthma, rhinitis, allergic airway syndrome, and allergic rhinobronchitis; wherein X1 is -S-, -O-, -N=N-. -NR7-, -CR7=CR8-, -CR7=N-, wherein R7 and R8 are independently hydrogen or C1-C3 alkyl; A is a carboxyl group -COOH, or a carboxyl bioisostere; rings Ar2 and Ar3 each independently represent a phenyl or 5- or 6­-membered monocyclic heteroaryl ring, or a bicyclic ring system consisting of a 5- or 6-membered carbocyclic or heterocyclic ring which is benz-fused or fused to a 5- or 6-membered monocyclic heteroaryl ring, said ring or ring system being optionally substituted; ring B is as defined for Ar2 and Ar3, or an optionally substituted N-­pyrrolidinyl, N-piperidinyl or N-azepinyl ring; s is 0 or 1; L1, L2 and L4 are linker radicals as defined in the description; Q1 and Q2 represent substituents as defined in the description.